‘The New Default’ – Industry Gives FDA Feedback On Biosimilar Streamlining Guidance
Developers Ask For No-CES Route As Standard; PhRMA Urges Caution
The FDA has been asked to make the streamlined biosimilars pathway the new default approach for applicants (Shutterstock) 
